Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Shares Issued (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Shares Issued for 5 consecutive years, with $124000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Issued fell 10.79% year-over-year to $124000.0, compared with a TTM value of $263000.0 through Dec 2025, up 89.21%, and an annual FY2025 reading of $304000.0, down 30.28% over the prior year.
  • Shares Issued was $124000.0 for Q4 2025 at Aligos Therapeutics, down from $139000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $78.3 million in Q3 2021 and bottomed at -$438000.0 in Q4 2023.
  • Average Shares Issued over 5 years is $6.6 million, with a median of $110000.0 recorded in 2021.
  • Peak annual rise in Shares Issued hit 4766.67% in 2023, while the deepest fall reached 336.76% in 2023.
  • Year by year, Shares Issued stood at $78.3 million in 2021, then tumbled by 99.76% to $185000.0 in 2022, then crashed by 336.76% to -$438000.0 in 2023, then soared by 131.74% to $139000.0 in 2024, then fell by 10.79% to $124000.0 in 2025.
  • Business Quant data shows Shares Issued for ALGS at $124000.0 in Q4 2025, $139000.0 in Q4 2024, and -$438000.0 in Q4 2023.